Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTISSIMO: GB-102 vs Aflibercept in Wet AMD
NCT03953079Phase 2Completed
- Sponsor
- CalciMedica
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GB-102 in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by CalciMedica. Primary endpoint: Time to First Rescue Treatment at 12 months. Started Sep 2019; status: completed.
02
Drugs
GB-102
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03953079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953079.